Amgen, Inc. (NASDAQ:AMGN) and UCB announced top-line results from the STRUCTURE trial (STudy evaluating effect of RomosozUmab Compared with Teriparatide in postmenopaUsal women with osteoporosis at high risk for fracture pReviously treated with bisphosphonatE therapy). The study (NCT01796301) met the primary endpoint, demonstrating a statistically significant difference in favor of romosozumab in the percent change of total hip bone mineral density (measured by DXA) through month 12.

STRUCTURE was a Phase 3, multi-center, international, randomized, open-label, teriparatide-controlled study that evaluated safety, tolerability and efficacy of romosozumab in women with postmenopausal osteoporosis. A total of 436 patients previously treated with bisphosphonate therapy received either subcutaneous romosozumab (210 mg monthly) or subcutaneous teriparatide (20 mcg daily) through to month 12.

The overall subject incidence of adverse events was generally balanced between arms. Adverse events in patients treated with romosozumab were similar to those previously reported and no new safety signals were detected. Adverse events reported in the romosozumab arm in more than five percent of patients were nasopharyngitis, arthralgia, back pain, headache and fall.

Further analysis of the Phase 3 STRUCTURE study results are ongoing and will be submitted to a future medical conference and for publication. (Original Source)

Shares of Amgen closed today at $147.46, down $4.32 or 2.85%. AMGN has a 1-year high of $181.81 and a 1-year low of $127.67. The stock’s 50-day moving average is $163.96 and its 200-day moving average is $159.78.

On the ratings front, Amgen has been the subject of a number of recent research reports. In a report issued on August 27, Piper Jaffray analyst Joshua Schimmer reiterated a Buy rating on AMGN, with a price target of $200, which represents a potential upside of 34.0% from where the stock is currently trading. Separately, on August 17, Deutsche Bank’s Robyn Karnauskas maintained a Buy rating on the stock and has a price target of $195.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Joshua Schimmer and Robyn Karnauskas have a total average return of 2.2% and 11.2% respectively. Schimmer has a success rate of 42.5% and is ranked #1333 out of 3742 analysts, while Karnauskas has a success rate of 61.7% and is ranked #192.

Overall, 4 research analysts have assigned a Hold rating and 6 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $178.90 which is 19.9% above where the stock opened today.